Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 May 2;75(754):e306-e315.
doi: 10.3399/BJGP.2024.0491. Print 2025 May.

Future Health Today and patients at risk of undiagnosed cancer: a pragmatic cluster randomised trial of quality- improvement activities in general practice

Affiliations
Randomized Controlled Trial

Future Health Today and patients at risk of undiagnosed cancer: a pragmatic cluster randomised trial of quality- improvement activities in general practice

Sophie Chima et al. Br J Gen Pract. .

Abstract

Background: Diagnosing cancer in general practice is complex, given the non-specific nature of many presenting symptoms and the overlap of potential diagnoses.

Aim: This trial aimed to evaluate the effectiveness of Future Health Today (FHT) - a technology that provides clinical decision support, auditing, and quality-improvement monitoring - on the appropriate follow-up of patients at risk of undiagnosed cancer.

Design and setting: Pragmatic, cluster randomised trial undertaken in general practices in Victoria and Tasmania, Australia.

Method: Practices were randomly assigned to receive recommendations for follow-up investigations for cancer (FHT cancer module) or the active control. Algorithms were applied to the electronic medical record, and used demographic information and abnormal test results that are associated with a risk of undiagnosed cancer (that is, anaemia/iron deficiency, thrombocytosis, and raised prostate-specific antigen) to identify patients requiring further investigation and provide recommendations for care. The intervention consisted of the FHT cancer module, a case-based learning series, and ongoing practice support. Using the intention-to-treat approach, the between-arm difference in the proportion of patients with abnormal test results who were followed up according to guidelines was determined at 12 months.

Results: In total, 7555 patients were identified as at risk of undiagnosed cancer. At 12 months post-randomisation, 76.0% of patients in the intervention arm had received recommended follow-up (21 practices, n = 2820/3709), compared with 70.0% in the control arm (19 practices, n = 2693/3846; estimated between-arm difference = 2.6% [95% confidence interval (CI)] = -2.8% to 7.9%; odds ratio = 1.15 [95% CI = 0.87 to 1.53]; P = 0.332).

Conclusion: The FHT cancer module intervention did not increase the proportion of patients receiving guideline-concordant care. The proportion of patients receiving recommended follow-up was high, suggesting a possible ceiling effect for the intervention.

Keywords: cancer; clinical decision support; diagnosis; general practice; primary care.

PubMed Disclaimer

Conflict of interest statement

The FHT software was developed by the University of Melbourne in collaboration with Western Health. These affiliations were displayed on the FHT dashboard and training materials. Craig Nelson, Jon Emery, and Jo-Anne Manski-Nankervis are the co-leads of the FHT programme, and Douglas Boyle leads the technical team that developed the software. Intellectual property related to FHT is owned by the University of Melbourne.

Figures

Figure 1.
Figure 1.
CONSORT flow diagram. aFrequent inclusion criteria that were not met included practice size, willingness to install GRHANITE, and incompatible practice software. bOther reasons for exclusion included recruitment targets being met in the trial and practices being lost to follow-up/non-responsive.
Figure 2.
Figure 2.
Forest plot showing estimated intervention effects (absolute differences), including planned sensitivity analyses for the primary outcome. a Difference in the proportion of patients followed up according to guidelines at 12 months between the intervention and the control arms. bSensitivity analysis adjusted for the practice participation in formalised quality improvement programme, patient’s age in years, cohort type, and patient’s sex. cSensitivity analysis without symptoms. N = number of investigations and n = number or participants.

Similar articles

Cited by

References

    1. Swann R, McPhail S, Witt J, et al. Diagnosing cancer in primary care: results from the National Cancer Diagnosis Audit. Br J Gen Pract. 2018 doi: 10.3399/bjgp17X694169. DOI: - DOI - PMC - PubMed
    1. Emery JD. The challenges of early diagnosis of cancer in general practice. Med J Aust. 2015;203(10):391–393. - PubMed
    1. Pearson C, Fraser J, Peake M, et al. Establishing population-based surveillance of diagnostic timeliness using linked cancer registry and administrative data for patients with colorectal and lung cancer. Cancer Epidemiol. 2019;61:111–118. - PMC - PubMed
    1. Mendonca SC, Abel GA, Saunders CL, et al. Pre-referral general practitioner consultations and subsequent experience of cancer care: evidence from the English Cancer Patient Experience Survey. Eur J Cancer Care. 2016;25(3):478–490. - PMC - PubMed
    1. Koo MM, Swann R, McPhail S, et al. Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study. Lancet Oncol. 2020;21(1):73–79. - PMC - PubMed

Publication types

LinkOut - more resources